[目的]研究白虎汤治疗对原发性肝癌TACE术后患者的基质金属酶水平及T细胞亚群的影响。[方法]以2012年10月~2014年7月我院收治的120例原发性肝癌并行TACE术后有发热症状的患者作为研究对象,根据随机数字表法分成研究组和对照组,每组60例。对照组患者进行常规的西医治疗,口服头孢克无分散片,2次/d,100mg/次,予消炎痛栓纳肛,2次/d,50mg/次,疗程10d。研究组在对照组基础上予以白虎汤加减治疗,早晚各一剂,疗程10d。一个疗程结束后评价2组患者的疗效及不良反应情况,比较治疗前后基质金属蛋白酶以及T细胞亚群的改变情况,同时评估随访半年、1年和2年患者的生存率和复发率。[结果]1个疗程治疗后研究组患者的有效率(90.00%)明显高于对照组(71.67%),差异有统计学意义(P<0.05)。治疗后研究组患者的MMP-1、MMP-3、MMP-9水平明显低于对照组,差异有统计学意义(P<0.05)。治疗后研究组患者CD3+、CD4+细胞亚群以及CD4+/CD8+比值显著升高,差异有统计学意义(P<0.05),治疗后研究组患者CD3+、CD4+细胞亚群以及CD4+/CD8+比值明显高于对照组,差异有统计学意义(P<0.05)。治疗后对照组患者的ALT和AST水平明显高于研究组,差异有统计学意义(P<0.05)。治疗后半年、1年、2年2组患者的生存率逐渐降低,且对照组患者的生存率低于研究组,仅随访第2年生存率之间的差异有统计学意义(P<0.05)。治疗后研究组半年、1年和2年内肿块的复发率均明显低于对照组,差异有统计学意义(P<0.05)。[结论]白虎汤治疗原发性肝癌TACE术后具有一定的疗效,且安全性高,能够增强患者的免疫保护和保肝降酶作用,对于术后复发具有一定的预防作用,有很好的临床应用前景。 [Objective] To investigate the effect of Baihu decoction on the level of matrix metalloproteinase and T lymphocyte subsets in patients with primary liver cancer after TACE. [Methods] From October 2012 to July 2014, 120 patients with primary hepatocellular carcinoma admitted to our hospital who had fever after TACE were divided into study group and control group according to random number table method, and each group 60 cases. Patients in the control group were treated with conventional western medicine. The oral cephalozapine-free dispersible tablets were administered twice a day, 100 mg once daily, and indomethacin suppositories were administered twice daily and 50 mg once daily for 10 days. The study group was treated with Baihu Decoction on the basis of the control group, one morning and one evening. The course of treatment was 10 days. After a course of treatment, the efficacy and adverse reactions of the two groups were evaluated. The changes of matrix metalloproteinase and T cell subsets before and after treatment were compared. The survival rates and recurrence rates of patients at 6 months, 1 year and 2 years follow-up were also evaluated. [Results] The effective rate (90.00%) of the study group after one course of treatment was significantly higher than that of the control group (71.67%), the difference was statistically significant (P <0.05). After treatment, the levels of MMP-1, MMP-3 and MMP-9 in the study group were significantly lower than those in the control group (P <0.05). After treatment, the ratio of CD3 +, CD4 + and CD4 + / CD8 + increased significantly in study group (P <0.05), and the ratio of CD3 +, CD4 + and CD4 + / CD8 + in study group was significantly higher than that in study group Control group, the difference was statistically significant (P <0.05). After treatment, the levels of ALT and AST in the control group were significantly higher than those in the study group, with significant difference (P <0.05). After 6 months, 1 year and 2 years, the survival rate of the two groups of patients decreased gradually, and the survival rate of the control group was lower than that of the study group. The difference between the two years of follow-up only showed statistically significant difference (P <0.05) . After treatment, the recurrence rates of the tumors in the study group at 6 months, 1 year and 2 years were significantly lower than those in the control group (P <0.05). [Conclusion] Baihu decoction has some curative effect after TACE for primary hepatocarcinoma, and it has high safety. It can enhance the patients’ immune protection and liver protection and enzyme-lowering effect, and has certain preventive effect on postoperative recurrence. It has good Clinical application prospects.